sorbin and SH3 domain containing 1Genealiases: CAP · FLAF2 · R85FL · SH3D5 · SH3P12 · SORB1
Q-omics provides the consensus-scored SORBS1 profile across patient tissues and cancer cell-line models. SORBS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SORBS1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SORBS1 protein abundance shows 31,295 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where SORBS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SORBS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SORBS1 survival associations across molecular data types. SORBS1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SORBS1 RNA expression–survival associations across cancer types. High SORBS1 expression shows unfavorable associations in BLCA and LUSC, but favorable associations in KIRC, BRCA, SCLC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SORBS1 RNA expression.
This table summarizes SORBS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SORBS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SORBS1 shows lower tumor expression in BLCA, THCA, LUAD, LUSC and BRCA and higher tumor expression in KIRC. The BLCA box plot shows higher SORBS1 RNA expression in normal versus tumor tissue (log2 FC = −4.970, t-test p < 0.001).
This table shows molecular features associated with SORBS1 in patient tissues and cancer cell lines. In patient samples, SORBS1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SORBS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SKIN.
